An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2- Period, Crossover Study to Evaluate Bioequivalence Between YHP2305 and YHR2404 in Healthy Subjects
Latest Information Update: 07 Oct 2024
At a glance
- Drugs YHP 2305 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Yuhan
- 04 Oct 2024 New trial record